Fish oil supplements in patients with chronic kidney disease
Charles J Ferro, Mark R Thomas, Sophia Khattak, Dimitrios Chanouzas, Jonathan N Townend · 2026
Read Fish oil supplements in patients with chronic kidney disease by Charles J Ferro, Mark R Thomas, Sophia Khattak, Dimitrios Chanouzas, Jonathan N Townend (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13261989.txt.
Description
Charles J Ferro and colleagues reviewed in 2026 fish oil supplements in chronic kidney disease, where heart disease drives most deaths. People on dialysis face the highest risk, and standard artery drugs help them little. Their review explains the many actions of omega-3 fats, from calming inflammation to stabilizing plaques.
Center stage goes to the PISCES trial, which gave high-dose fish oil to 1,228 dialysis patients for three and a half years. The daily dose paired 1.6 grams of EPA with a smaller amount of DHA. Events in the main combined outcome fell by forty-three percent, with matching drops in cardiac death, heart attack, and stroke. Earlier fish oil studies in kidney disease were small and inconclusive. The authors call for larger trials to confirm the result before routine adoption.
Catalog record
| CREATOR | Charles J Ferro, Mark R Thomas, Sophia Khattak, Dimitrios Chanouzas, Jonathan N Townend |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |